The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people
- PMID: 26240429
- PMCID: PMC4528826
- DOI: 10.1098/rstb.2014.0214
The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people
Abstract
In addition to causing distress and disability to the individual, neuropsychiatric disorders are also extremely expensive to society and governments. These disorders are both common and debilitating and impact on cognition, functionality and wellbeing. Cognitive enhancing drugs, such as cholinesterase inhibitors and methylphenidate, are used to treat cognitive dysfunction in Alzheimer's disease and attention deficit hyperactivity disorder, respectively. Other cognitive enhancers include specific computerized cognitive training and devices. An example of a novel form of cognitive enhancement using the technological advancement of a game on an iPad that also acts to increase motivation is presented. Cognitive enhancing drugs, such as methylphenidate and modafinil, which were developed as treatments, are increasingly being used by healthy people. Modafinil not only affects 'cold' cognition, but also improves 'hot' cognition, such as emotion recognition and task-related motivation. The lifestyle use of 'smart drugs' raises both safety concerns as well as ethical issues, including coercion and increasing disparity in society. As a society, we need to consider which forms of cognitive enhancement (e.g. pharmacological, exercise, lifelong learning) are acceptable and for which groups (e.g. military, doctors) under what conditions (e.g. war, shift work) and by what methods we would wish to improve and flourish.
Keywords: cognitive enhancers; cognitive training; game; neuroethics; schizophrenia; smart drugs.
Figures

Similar articles
-
Neuroethical issues in cognitive enhancement: Modafinil as the example of a workplace drug?Brain Neurosci Adv. 2019 Feb 15;3:2398212818816018. doi: 10.1177/2398212818816018. eCollection 2019 Jan-Dec. Brain Neurosci Adv. 2019. PMID: 32166175 Free PMC article. Review.
-
Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people.Lancet Psychiatry. 2015 Apr;2(4):357-62. doi: 10.1016/S2215-0366(15)00004-8. Epub 2015 Mar 31. Lancet Psychiatry. 2015. PMID: 26360089
-
Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.Clin Pharmacol Ther. 2017 Feb;101(2):170-172. doi: 10.1002/cpt.457. Epub 2016 Sep 23. Clin Pharmacol Ther. 2017. PMID: 27557349
-
Neuroethical issues in cognitive enhancement.J Psychopharmacol. 2011 Feb;25(2):197-204. doi: 10.1177/0269881109106926. Epub 2010 Mar 8. J Psychopharmacol. 2011. PMID: 20212064 Review.
-
Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.Br J Pharmacol. 2017 Oct;174(19):3257-3267. doi: 10.1111/bph.13813. Epub 2017 May 12. Br J Pharmacol. 2017. PMID: 28427114 Free PMC article. Review.
Cited by
-
Pills or Push-Ups? Effectiveness and Public Perception of Pharmacological and Non-Pharmacological Cognitive Enhancement.Front Psychol. 2015 Dec 2;6:1852. doi: 10.3389/fpsyg.2015.01852. eCollection 2015. Front Psychol. 2015. PMID: 26696922 Free PMC article.
-
The Issue of "Smart Drugs" on the Example of Modafinil: Toxicological Analysis of Evidences and Biological Samples.J Xenobiot. 2025 Jan 17;15(1):15. doi: 10.3390/jox15010015. J Xenobiot. 2025. PMID: 39846547 Free PMC article.
-
Cognitive Enhancement: Unanswered Questions About Human Psychology and Social Behavior.Sci Eng Ethics. 2021 Mar 23;27(2):19. doi: 10.1007/s11948-021-00294-w. Sci Eng Ethics. 2021. PMID: 33759032 Free PMC article.
-
Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing.Int J Neuropsychopharmacol. 2018 Apr 1;21(4):345-354. doi: 10.1093/ijnp/pyx112. Int J Neuropsychopharmacol. 2018. PMID: 29206921 Free PMC article. Clinical Trial.
-
A decision-neuroscientific intervention to improve cognitive recovery after stroke.Brain. 2021 Jul 28;144(6):1764-1773. doi: 10.1093/brain/awab128. Brain. 2021. PMID: 33742664 Free PMC article. Clinical Trial.
References
-
- Care Quality Commission. 2013. The safer management of controlled drugs: annual report 2012 See http://www.cqc.org.uk/sites/default/files/documents/cdar_2012.pdf (15.12.2014).
-
- Boseley S. 2014. £200,000 ‘smart’ drugs seizure prompts alarm over rising UK sales. The Guardian, London, Friday 24 October 2014.
-
- Presidential Commission for the Study of Bioethics. 2014. GRAY MATTERS: integrative approaches for neuroscience, ethics, and society See http://www.bioethics.gov/sites/default/files/Gray%20Matters%20Vol%201.pdf (29.11.2014).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials